Merck & Co. Inc. (MRK)

67.37
0.91 1.37
NYSE : Health Technology
Prev Close 66.46
Open 66.73
Day Low/High 66.47 / 67.57
52 Wk Low/High 52.83 / 66.99
Volume 10.88M
Avg Volume 8.92M
Exchange NYSE
Shares Outstanding 2.66B
Market Cap 177.44B
EPS 0.90
P/E Ratio 133.44
Div & Yield 1.92 (2.89%)
Senator Asks Drug Companies What They'll Do With Extra Cash From Big Tax Cut

Senator Asks Drug Companies What They'll Do With Extra Cash From Big Tax Cut

Senator Tina Smith wants some answers from a group of Big Pharma companies about how the new cash flowing from the corporate tax break will be spent.

Merck To Present New Data From Studies Of Investigational HIV Therapies Doravirine And MK-8591 At CROI 2018

Merck To Present New Data From Studies Of Investigational HIV Therapies Doravirine And MK-8591 At CROI 2018

Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced that data from studies of Merck's robust HIV pipeline, including doravirine, a late-stage investigational non-nucleoside reverse...

Merck Becomes #22 Most Shorted Dow Stock, Replacing UnitedHealth Group

Merck Becomes #22 Most Shorted Dow Stock, Replacing UnitedHealth Group

The most recent short interest data has been released for the 02/15/2018 settlement date, and we here at Dividend Channel like to sift through this fresh data and order the underlying components of the Dow Jones Industrial Average by "days to cover." There are a number of ways to look at short data, for example the total number of shares short; but one metric that we find particularly useful is the "days to cover" metric because it considers both the total shares short and the average daily volume of shares typically traded. The number of shares short is then compared to the average daily volume, in order to calculate the total number of trading days it would take to close out all of the open short positions if every share traded represented a short position being closed.

LYNPARZA® (olaparib) Receives Positive EU CHMP Opinion In Platinum-Sensitive Relapsed Ovarian Cancer

LYNPARZA® (olaparib) Receives Positive EU CHMP Opinion In Platinum-Sensitive Relapsed Ovarian Cancer

AstraZeneca and Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency has adopted a positive...

Http://www.merck.com

Http://www.merck.com

Merck (NYSE: MRK), known as MSD outside the United States and Canada, and Viralytics Limited (ASX: VLA, OTC: VRACY) today announced that the companies have signed a definitive agreement under which it is proposed that...

Jim Cramer: These 4 Stocks Seem Attractive Right Here

Jim Cramer: These 4 Stocks Seem Attractive Right Here

There is nothing wrong with Intel, Johnson & Johnson, 3M and Apple.

The Jury Is Still Out on Merck

The Jury Is Still Out on Merck

When the broad market rallies and your stock does not participate there is a message there and that bothers me.

Selumetinib Granted Orphan Drug Designation By The U.S. FDA For Neurofibromatosis Type 1

Selumetinib Granted Orphan Drug Designation By The U.S. FDA For Neurofibromatosis Type 1

AstraZeneca and Merck (NYSE:MRK), known as MSD outside the U.S.

Merck Announces Discontinuation Of APECS Study Evaluating Verubecestat (MK-8931) For The Treatment Of People With Prodromal Alzheimer's Disease

Merck Announces Discontinuation Of APECS Study Evaluating Verubecestat (MK-8931) For The Treatment Of People With Prodromal Alzheimer's Disease

Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced that it will be stopping protocol 019, also known as the APECS study, a Phase 3 study evaluating verubecestat (MK-8931), an...

Volatility Is Still in Charge: Cramer's 'Mad Money' Recap (Friday, 2/9/18)

Volatility Is Still in Charge: Cramer's 'Mad Money' Recap (Friday, 2/9/18)

Jim Cramer tackles the volatility issue and outlines the game plan for next week.

Taking Merck's Temperature

Taking Merck's Temperature

How far MRK can travel in the next few weeks is key.

Jim Cramer: These 4 Stocks Seem Attractive Right Here

Jim Cramer: These 4 Stocks Seem Attractive Right Here

There is nothing wrong with Intel, Johnson & Johnson, 3M and Apple.

Why Investors Shouldn't Worry About Trump's Tough Talk on Drug Prices

Why Investors Shouldn't Worry About Trump's Tough Talk on Drug Prices

While Donald Trump's tweets can shake up pharmaceutical stocks, history suggests that investors have little to fear from the president's drug pricing rhetoric.

Merck Becomes #20 Most Shorted Dow Stock, Replacing Walt Disney C

Merck Becomes #20 Most Shorted Dow Stock, Replacing Walt Disney C

The most recent short interest data has been released for the 01/12/2018 settlement date, and we here at Dividend Channel like to sift through this fresh data and order the underlying components of the Dow Jones Industrial Average by "days to cover." There are a number of ways to look at short data, for example the total number of shares short; but one metric that we find particularly useful is the "days to cover" metric because it considers both the total shares short and the average daily volume of shares typically traded. The number of shares short is then compared to the average daily volume, in order to calculate the total number of trading days it would take to close out all of the open short positions if every share traded represented a short position being closed.

First-of-its-Kind Study Reveals Concern About The Future Of The Veterinary Profession

First-of-its-Kind Study Reveals Concern About The Future Of The Veterinary Profession

Merck Animal Health (known as MSD Animal Health outside the United States and Canada) today announced the results of a large, well-controlled study with veterinarians designed to definitively quantify the prevalence of...

Centene, LabCorp Among Healthcare Stock Gainers

Centene, LabCorp Among Healthcare Stock Gainers

Centene and Laboratory Corp. of America were among the healthcare stocks in the green on Tuesday, Feb. 6, amid a volatile trading day in the stock market.

Pharma Execs Talk M&A, Drug Pricing Pressures on Earnings Calls

Pharma Execs Talk M&A, Drug Pricing Pressures on Earnings Calls

'I think everybody is looking at potential combinations and consolidations,' Pfizer CEO Ian Read said on an earnings call on Tuesday, Jan. 30.

It's Bad, but It's Not a Crash: Cramer's 'Mad Money' Recap (Friday 2/2/18)

It's Bad, but It's Not a Crash: Cramer's 'Mad Money' Recap (Friday 2/2/18)

In a special edition of Mad money, Jim Cramer examines this brutal decline and lays out the game plan for next week -- live from Minneapolis ahead of the Super Bowl.

Shopify, Kinder Morgan, Pfizer: 'Mad Money' Lightning Round

Shopify, Kinder Morgan, Pfizer: 'Mad Money' Lightning Round

Jim Cramer highlights Shopify, Kinder Morgan, Thermo Fisher Scientific, Radius Health, Merck, Pfizer and more.

Dow Gets Walloped, Falls 665 Points as Bond Yields Spike

Dow Gets Walloped, Falls 665 Points as Bond Yields Spike

Stocks plunge and Treasury yields spike after the U.S. adds 200,000 jobs to payrolls in January and wages increase.

Stocks Slide and Amazon's Profit Soars - 5 Things You Must Know

Stocks Slide and Amazon's Profit Soars - 5 Things You Must Know

U.S. stock futures are falling sharply on Friday as bond yields jump, Apple posts a mixed quarter, and Wall Street awaits the U.S. jobs report for January.

Unfortunately Red Hot Economic Data Supports Higher Interest Rates

Unfortunately Red Hot Economic Data Supports Higher Interest Rates

Economic conditions seem to be improving for laborers. Perhaps rapidly.

Financial Highlights Package

Financial Highlights Package

Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced financial results for the fourth quarter and full year of 2017.

Black History Month on Wall Street

Black History Month on Wall Street

This Black History month, we are taking a look at the African Americans who have made it to the C-Suite and are making a difference. And sadly, there are not many. Watch our video to learn the names you should know now.

Eli Lilly Beats Estimates, but Shares Head Lower Amid Diabetes Concerns

Eli Lilly Beats Estimates, but Shares Head Lower Amid Diabetes Concerns

BMO Capital Markets analyst Alex Arfaei says the fourth-quarter results show how dependent the drugmaker is on major diabetes assets 'and doesn't alleviate our concerns.'

Pro Football Hall Of Famer And Cancer Survivor Jim Kelly Joins Merck To Challenge America To Raise Funds For The Cancer Community

Pro Football Hall Of Famer And Cancer Survivor Jim Kelly Joins Merck To Challenge America To Raise Funds For The Cancer Community

With an estimated 1.6 million Americans diagnosed in 2017 alone, cancer not only impacts those diagnosed but their friends and family as well.

Healthcare Panic May Be Overblow; Cryptocurrency Trading Volumes Dip -- ICYMI

Healthcare Panic May Be Overblow; Cryptocurrency Trading Volumes Dip -- ICYMI

Here's what you need to know now for Tuesday, Jan. 30.

Merck Becomes #20 Most Shorted Dow Stock, Replacing Walt Disney

Merck Becomes #20 Most Shorted Dow Stock, Replacing Walt Disney

The most recent short interest data has been released for the 98/16/2017 settlement date, and we here at Dividend Channel like to sift through this fresh data and order the underlying components of the Dow Jones Industrial Average by "days to cover." There are a number of ways to look at short data, for example the total number of shares short; but one metric that we find particularly useful is the "days to cover" metric because it considers both the total shares short and the average daily volume of shares typically traded. The number of shares short is then compared to the average daily volume, in order to calculate the total number of trading days it would take to close out all of the open short positions if every share traded represented a short position being closed.

Tax Reform Benefits More About Paying Down Debt Than M&A: BofA Merrill Lynch

Tax Reform Benefits More About Paying Down Debt Than M&A: BofA Merrill Lynch

As earnings season continues, companies are taking investor calls as an opportunity to explain just what they have planned for their tax reform-related windfalls of cash.

TheStreet Quant Rating: B+ (Buy)